-
公开(公告)号：US20230213519A1
公开(公告)日：2023-07-06
申请号：US17911819
申请日：2021-03-15
Applicant: 4TEEN4 PHARMACEUTICALS GMBH
Inventor： Andreas BERGMANN
IPC: G01N33/573 , G01N33/569 , A61P31/14 , A61P9/00 , C07K16/40
CPC classification number: G01N33/573 , G01N33/56983 , A61P31/14 , A61P9/00 , C07K16/40 , G01N2333/165 , G01N2333/96433 , G01N2800/52 , G01N2800/325 , C07K2317/76 , C07K2317/34 , C07K2317/24 , C07K2317/92 , A61K2039/505
Abstract: Subject matter of the present invention is a method for (a) diagnosing or predicting the risk of life-threatening deterioration or an adverse event or (b) diagnosing or prognosing the severity or (c) predicting or monitoring the success of a therapy or intervention or (d) therapy guidance or therapy stratification or (e) patient management in a patient infected with a coronavirus, the method comprising:
determining the level of dipeptidyl peptidase 3 (DPP3) in a sample of bodily fluid of said patient,
comparing said level of determined DPP3 to a pre-determined threshold, and
correlating said level of determined DPP3 with the risk of life-threatening deterioration or an adverse event, or
correlating said level of determined DPP3 with the severity, or
correlating said level of determined DPP3 with the success of a therapy or intervention, or
correlating said level of DPP3 with a certain therapy or intervention, or
correlating said level of DPP3 with the management of said patient.
Subject matter of the present invention is an inhibitor of the activity of DPP3 for use in therapy or intervention in a patient infected with a coronavirus.-
公开(公告)号：US11530276B2
公开(公告)日：2022-12-20
申请号：US16758881
申请日：2018-10-24
Applicant: 4TEEN4 Pharmaceuticals GmbH
Inventor： Andreas Bergmann
IPC: C07K16/40
Abstract: The present invention provides binder directed to and binding to a DPP3 protein or functional derivative thereof and its use in a method of prevention or treatment of diseases or acute conditions in a patient, wherein said disease or acute condition is associated with oxidative stress. With this context, specifically the present invention provides a binder being directed to and binding to an epitope according to SEQ ID NO.: 2, wherein said epitope is comprised in a DPP3 protein or a functional derivative thereof, and wherein said DPP3 binder recognizes and binds to at least three amino acids of SEQ ID NO.: 2.
-
公开(公告)号：US20220307065A1
公开(公告)日：2022-09-29
申请号：US17637518
申请日：2020-08-28
Applicant: 4TEEN4 Pharmaceuticals GmbH
Inventor： Andreas BERGMANN
Abstract: Subject matter of the present invention is a method for predicting or diagnosing a refractory shock in a subject that either runs into shock or that has developed shock, wherein said method is comprising the steps: determining the level of DPP3 in a sample of bodily fluid of said subject; comparing said level of determined DPP3 to a predetermined threshold, wherein said subject is predicted to run into refractory shock or is diagnosed as having refractory shock if said determined level of DPP3 is above said predetermined threshold. Further subject matter relates to vasopressors, angiotensin-receptor agonists and/or precursors thereof, inhibitors of the activity of DPP3 and anti-ADM antibodies for use in therapy of shock in a subject that either runs into shock or that has developed shock.
-
公开(公告)号：US20220211798A1
公开(公告)日：2022-07-07
申请号：US17416197
申请日：2019-12-20
Applicant: 4TEEN4 PHARMACEUTICALS GMBH
Inventor： Andreas BERGMANN
Abstract: Subject matter of the present invention is an angiotensin-receptor-agonist and/or a precursor thereof for use in the treatment of a disease in a subject, ⋅wherein said disease is selected from the group comprising heart failure, chronic heart failure, acute heart failure (AHF), myocardial infarction (MI), stroke, liver failure, burn injuries, traumatic injuries, severe infection (microbial, viral (e.g. AIDS), parasitic diseases (e.g. Malaria)), SIRS or sepsis, cancer, acute kidney injury (AKI), CNS disorders (e.g. seizures, neurodegenerative diseases), autoimmune diseases, vascular diseases, hypotension and shock, and ⋅wherein said subject has an amount of DPP3 protein and/or DPP3 activity in a sample of bodily fluid that is above a predetermined threshold.
-
公开(公告)号：US20240385197A1
公开(公告)日：2024-11-21
申请号：US18338805
申请日：2023-06-21
Applicant: 4TEEN4 PHARMACEUTICALS GMBH
Inventor： Andreas BERGMANN
IPC: G01N33/58 , A61K39/00 , C07K16/40 , G01N33/543 , G01N33/574 , G01N33/68
Abstract: The present invention is directed to methods for determining active DPP3 in a bodily fluid sample, an assay or kit for determining active DPP3 in a bodily fluid sample, a method for diagnosing a disease or condition in a subject accompanied by or related to necrotic processes and methods of treating or preventing said disease.
-
Patent Agency Ranking
6.发明公开公开(公告)号：US20230193348A1
公开(公告)日：2023-06-22
申请号：US17802799
申请日：2021-02-26
Applicant: 4TEEN4 PHARMACEUTICALS GMBH
Inventor： Andreas BERGMANN
IPC: C12Q1/37 , G01N33/573
CPC classification number: C12Q1/37 , G01N33/573 , G01N2800/26 , G01N2800/52
Abstract: The present application is directed to to a method for therapy guidance and/ or therapy monitoring and/ or therapy stratification in a patient with shock and/or in a patient running into shock. In particular, the method comprises providing a sample from said patient, determining a level of DPP3 in said sample, and wherein the level of DPP3 in said sample is indicative of whether a treatment with an anti-ADM antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold is required. In a preferred embodiment of the invention, the method comprises additionally determining in a sample from said patient a level of ADM-NH2.
-
公开(公告)号：US20200378977A1
公开(公告)日：2020-12-03
申请号：US16919449
申请日：2020-07-02
Applicant: 4TEEN4 PHARMACEUTICALS GMBH
Inventor： Andreas BERGMANN
IPC: G01N33/58 , G01N33/574 , G01N33/68 , C07K16/40 , G01N33/543
Abstract: The present invention is directed to methods for determining active DPP3 in a bodily fluid sample, an assay or kit for determining active DPP3 in a bodily fluid sample, a method for diagnosing a disease or condition in a subject accompanied by or related to necrotic processes and methods of treating or preventing said disease.
-
公开(公告)号：US20230295344A1
公开(公告)日：2023-09-21
申请号：US17984611
申请日：2022-11-10
Applicant: 4TEEN4 Pharmaceuticals GmbH
Inventor： Andreas BERGMANN
IPC: C07K16/40
CPC classification number: C07K16/40 , C07K2317/24 , C07K2317/34 , C07K2317/51 , C07K2317/515 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C07K2318/20
Abstract: The present invention provides binder directed to and binding to a DPP3 protein or functional derivative thereof and its use in a method of prevention or treatment of diseases or acute conditions in a patient, wherein said disease or acute condition is associated with oxidative stress. With this context, specifically the present invention provides a binder being directed to and binding to an epitope according to SEQ ID NO.: 2, wherein said epitope is comprised in a DPP3 protein or a functional derivative thereof, and wherein said DPP3 binder recognizes and binds to at least three amino acids of SEQ ID NO.: 2.
-
公开(公告)号：US11726094B2
公开(公告)日：2023-08-15
申请号：US16919449
申请日：2020-07-02
Applicant: 4TEEN4 PHARMACEUTICALS GMBH
Inventor： Andreas Bergmann
IPC: G01N33/58 , G01N33/574 , G01N33/68 , C07K16/40 , G01N33/543 , A61K39/00
CPC classification number: G01N33/581 , C07K16/40 , G01N33/54306 , G01N33/574 , G01N33/6854 , G01N33/6893 , A61K2039/505 , A61K2039/545 , C07K2317/73 , C07K2317/76 , C07K2317/90 , G01N2333/948 , G01N2800/24 , G01N2800/26 , G01N2800/325 , G01N2800/347 , Y02A50/30
Abstract: The present invention is directed to methods for determining active DPP3 in a bodily fluid sample, an assay or kit for determining active DPP3 in a bodily fluid sample, a method for diagnosing a disease or condition in a subject accompanied by or related to necrotic processes and methods of treating or preventing said disease.
-
公开(公告)号：US20210206876A1
公开(公告)日：2021-07-08
申请号：US16758881
申请日：2018-10-24
Applicant: 4TEEN4 Pharmaceuticals GmbH
Inventor： Andreas BERGMANN
IPC: C07K16/40
Abstract: The present invention provides binder directed to and binding to a DPP3 protein or functional derivative thereof and its use in a method of prevention or treatment of diseases or acute conditions in a patient, wherein said disease or acute condition is associated with oxidative stress. With this context, specifically the present invention provides a binder being directed to and binding to an epitope according to SEQ ID NO.: 2, wherein said epitope is comprised in a DPP3 protein or a functional derivative thereof, and wherein said DPP3 binder recognizes and binds to at least three amino acids of SEQ ID NO.: 2.
-
-
-
-
-
-
-
-
-
Search Results
10
records
(took 0.022 seconds)
